Brief: Cidara Therapeutics Announces First Subjects Dosed In Phase 2B Navigate Trial Evaluating Cd388 For The Prevention Of Seasonal Influenza
23/09/2024 14:21
Sept 23 (Reuters) - Cidara Therapeutics Inc CDTX.O :
* CIDARA THERAPEUTICS ANNOUNCES FIRST SUBJECTS DOSED IN
PHASE 2B
NAVIGATE TRIAL EVALUATING CD388 FOR THE PREVENTION OF SEASONAL
INFLUENZA
Source text for Eikon: ID:nGNXgV8WQ
Further company coverage: CDTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cidara Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merck Seeks Up To $8 Billion In Us Bond Sale Tied To Cidara Deal - Bloomberg News
Merck rises after Wells Fargo upgrades stock to 'overweight'
Factbox: Major deals involving U.S. drugmakers and biotechs over the past decade